Hybrids of dendritic cells and tumor cells generated by electrofusion simultaneously present immunodominant epitopes from multiple human tumor-associated antigens in the context of MHC class I and class II molecules.

Hybrids of dendritic cells and tumor cells generated by electrofusion simultaneously present immunodominant epitopes from multiple human tumor-associated antigens in the context of MHC class I and class II molecules.

Item

http://www.wikidata.org/entity/Q36908547

Q36908547

about

Vaccination with dendritic cell/tumor fusion cells results in cellular and humoral antitumor immune responses in patients with multiple myeloma Lenalidomide enhances anti-myeloma cellular immunity Semiallogenic fusions of MSI(+) tumor cells and activated B cells induce MSI-specific T cell responses Interleukin-7 gene-modified dendritic cells reduce pulmonary tumor burden in spontaneous murine bronchoalveolar cell carcinoma.Dendritic cell-based vaccines: barriers and opportunities Immunologic monitoring of cellular responses by dendritic/tumor cell fusion vaccines.Dendritic cells pulsed with leukemia cell-derived exosomes more efficiently induce antileukemic immunities.Dendritic cells in melanoma immunotherapy.Dendritic cell fusion vaccines for cancer immunotherapy.Presentation of tumor antigens by dendritic cells genetically modified with viral and nonviral vectors Immune responses in the draining lymph nodes against cancer: implications for immunotherapy.Thymic expression of peripheral tissue antigens in humans: a remarkable variability among individuals A microfluidic approach towards hybridoma generation for cancer immunotherapy STAT3- and STAT5-dependent pathways competitively regulate the pan-differentiation of CD34pos cells into tumor-competent dendritic cells Comparison of cytotoxic T lymphocyte responses against pancreatic cancer induced by dendritic cells transfected with total tumor RNA and fusion hybrided with tumor cell.Vaccination with dendritic cell/tumor fusions following autologous stem cell transplant induces immunologic and clinical responses in multiple myeloma patients.Cell fusion: from hybridoma to dendritic cell-based vaccine.Purified dendritic cell-tumor fusion hybrids supplemented with non-adherent dendritic cells fraction are superior activators of antitumor immunity.Optimization of dendritic cell loading with tumor cell lysates for cancer immunotherapy.Cancer vaccine by fusions of dendritic and cancer cells.Induction of antitumor immunity by semi-allogeneic and fully allogeneic electrofusion products of tumor cells and dendritic cells.Cancer immunotherapy by fusions of dendritic cells and tumor cells.Regulation of tumor immunity by tumor/dendritic cell fusions Immune response to cancer and its regulation in regional lymph nodes.Fusions of dendritic cells with breast carcinoma stimulate the expansion of regulatory T cells while concomitant exposure to IL-12, CpG oligodeoxynucleotides, and anti-CD3/CD28 promotes the expansion of activated tumor reactive cells.Update on Mucin-1 immunotherapy in cancer: a clinical perspective.Dynamic analysis of immune and cancer cell interactions at single cell level in microfluidic droplets.Dendritic Cell Therapies for Hematologic Malignancies.High-resolution analyses of cell fusion dynamics in a biochip.Anti-tumor activity of Acinetobacter baumannii outer membrane protein A on dendritic cell-based immunotherapy against murine melanoma.In vivo anti-tumor effect of hybrid vaccine of dendritic cells and esophageal carcinoma cells on esophageal carcinoma cell line 109 in mice with severe combined immune deficiency.Generation of anti-tumour effector T cells from naïve T cells by stimulation with dendritic/tumour fusion cells.Dendritic cells fused with allogeneic breast cancer cell line induce tumor antigen-specific CTL responses against autologous breast cancer cells.Exposure to the electrofusion process can increase the immunogenicity of human cells.Cancer immunotherapy by fusions of dendritic and tumour cells and rh-IL-12.Cancer vaccine development: designing tumor cells for greater immunogenicity.The impact of electrical charge on the viability and physiology of dendritic cells.Dendritic Cell-Based Immunotherapy

P2860

Q33732491-46A6331D-9BC5-40E6-BBD7-29CF79110B53 Q33903133-90FA3205-7899-42A9-9E13-BAACAA43926B Q34028964-53E91752-8D73-4BC0-ADAA-D825811738C5 Q34646946-8B3CEEEB-3EDE-4B51-9650-ABF33FAAF0A7 Q34661797-27548E0A-4712-44FE-B83E-B0AF665D2198 Q34898366-F142CC30-2CDF-4C68-9137-FFB94BB211A1 Q35119026-99EE4FB5-189B-493A-AEAF-106902187AF3 Q36115652-C678FDD8-B237-44E1-AEAF-3E605DE62493 Q36150517-54701C87-8D4C-4521-A58B-D76E8F09C500 Q36327106-EBF47807-B0B8-4B6A-AC6B-F11802C39B18 Q36504940-6F164438-3A0D-46A6-8C0F-1398E60C3449 Q36628887-F79BF061-DAD0-4152-A6B0-326C0DFD4403 Q36629413-6B7B6374-BC63-4839-A1D8-D4C62815D8A6 Q36843729-A366E571-AED6-4A32-9F25-1327AB23D76F Q37071139-C900FC87-79D9-40A4-AF1D-FA00CACECE1B Q37128664-ADD9D75D-75D1-40DD-B0E7-2737141D2C41 Q37259630-73A1CDB7-F771-4644-987B-170A5E9181F8 Q37510538-88FDF915-BDF2-4C9A-B36F-F460BD5AB88A Q37513293-53872B31-BD60-4C1E-BA29-996A17554C80 Q37698219-0F10EA79-0F0F-41AC-95DC-009D89158C4B Q37700493-240171A7-4091-43D9-A31C-E3BE84E5D22C Q37773276-46A01163-F32D-44BB-825D-691697C70501 Q37806963-944A5D5C-3179-4A20-81D6-0C375D249FF0 Q37863623-23B95077-356F-44E7-9779-7101B85A6CB3 Q38289899-3CD856BC-AADE-440C-9833-3C4E080BDDC4 Q38603410-E074B8A3-5245-4881-86CF-68B2F3F66C54 Q38735074-AC298FCA-0862-4B88-AF5B-ECB323329C84 Q39289930-F714BE99-9FC2-4A20-BEC4-7D639F1C33E5 Q39296216-2F9FC497-3423-4065-B01D-1A52FEF0E5C8 Q39973274-EFA39597-ABA3-48EA-9D84-E78876AD6A37 Q40008890-C2FE748D-9784-4AA9-86F4-B817CA163D75 Q40063917-4FADB57C-6412-47C4-9ACA-36EC635B6DAC Q40190838-E79C8B30-44B1-40EF-A160-23C2CD032B5A Q40415230-A7ABBB5D-D4FB-4863-BF7E-DF45D83E22D3 Q40511274-90AD0A47-5AC2-4A42-9196-173788888FA5 Q42384053-1A41917C-A94D-4E47-A46D-B0C3A97C5609 Q46777207-A1DA8E1A-A9C6-4F85-8BA5-419BB258CD53 Q58409682-3DFD7841-4632-4357-95B2-FAC6E8E54C64

P2860

Hybrids of dendritic cells and tumor cells generated by electrofusion simultaneously present immunodominant epitopes from multiple human tumor-associated antigens in the context of MHC class I and class II molecules.

Item

http://www.wikidata.org/entity/Q36908547

description

2003 nî lūn-bûn

@nan

2003年の論文

@ja

2003年論文

@yue

2003年論文

@zh-hant

2003年論文

@zh-hk

2003年論文

@zh-mo

2003年論文

@zh-tw

2003年论文

@wuu

2003年论文

@zh

2003年论文

@zh-cn

name

Hybrids of dendritic cells and ...... lass I and class II molecules.

@en

type

Item

label

Hybrids of dendritic cells and ...... lass I and class II molecules.

@en

prefLabel

Hybrids of dendritic cells and ...... lass I and class II molecules.

@en

P1476

Hybrids of dendritic cells and ...... lass I and class II molecules.

@en

P2093

Cormac DePan

http://www.w3.org/2001/XMLSchema#string

John P Riley

http://www.w3.org/2001/XMLSchema#string

Maria R Parkhurst

http://www.w3.org/2001/XMLSchema#string

Steven A Rosenberg

http://www.w3.org/2001/XMLSchema#string

Suyu Shu

http://www.w3.org/2001/XMLSchema#string

P2860

Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes

Identification of human cancers deficient in antigen processing

A new era for cancer immunotherapy based on the genes that encode cancer antigens

Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha

Pre-existing immunity to tyrosinase-related protein (TRP)-2, a new TRP-2 isoform, and the NY-ESO-1 melanoma antigen in a patient with a dramatic response to immunotherapy

Immunobiology of dendritic cells

Characterization of peptides bound to the class I MHC molecule HLA-A2.1 by mass spectrometry.

Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines.

A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma

RNA-transfected dendritic cells in cancer immunotherapy.

P304

5317-5325

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4049/JIMMUNOL.170.10.5317

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

170

http://www.w3.org/2001/XMLSchema#string

P577

2003-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7340107

http://www.w3.org/2001/XMLSchema#string

P698

12734382

http://www.w3.org/2001/XMLSchema#string

P932

2553207

http://www.w3.org/2001/XMLSchema#string

Hybrids of dendritic cells and tumor cells generated by electrofusion simultaneously present immunodominant epitopes from multiple human tumor-associated antigens in the context of MHC class I and class II molecules.

about

P2860

P2860

Hybrids of dendritic cells and tumor cells generated by electrofusion simultaneously present immunodominant epitopes from multiple human tumor-associated antigens in the context of MHC class I and class II molecules.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P5875

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P5875

P698

P932